Evaluasi Antibodi dan Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin COVID-19 AstraZeneca Dosis Lengkap di Sentra Vaksin UTA'45 Jakarta

Stefanus Lukas

doi:10.24198/ijpst.v11i3.54268

Evaluasi Antibodi dan Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin COVID-19 AstraZeneca Dosis Lengkap di Sentra Vaksin UTA'45 Jakarta

Stefanus Lukas

Abstrak

Latar Belakang: AstraZeneca merupakan vaksin vektor virus. Vaksin adalah alat penting untuk membatasi kesehatan pandemi COVID -19. Vaksin ini memiliki metode yang lebih canggih yaitu menggunakan virus yang dimodifikasi untuk memicu antibodi guna menciptakan kekebalan kelompok (herd immunity) pada masyarakat. Tujuan : Mengevaluasi hubungan pemberian vaksin AstraZeneca terhadap nilai titer antibodi dan KIPI. Metode : Penelitian ini menggunakan metode retrospektif dan prospektif kohort Responden yang telah memenuhi kriteria inklusi dan ekslusi akan dijadikan sebagai responden dalam penelitian. Sebanyak 113 responden melakukan vaksinasi COVID-19 AstraZaneca dosis lengkap di Pusat Vaksin UTA’45 Jakarta. Setelah 7 hari pasca-vaksinasi, dilakukan pengukuran kadar titer antibodi dan gejala lokal dan sistemik KIPI selama 7 hari. Hasil: Jumlah responden yang pernah terpapar COVI-19 signfikan secara statistik terjadi pada jenis kelamin laki-laki, umur dibawah 35 tahun, disertai dengan penyakit penyerta (komorbid), aktif berolahraga, merokok dan tidak meminum alkohol. Sebanyak 38 (88.4%) orang dari 43 (38,05%) responden memiliki titer antibodi tinggi dan 5 orang (11,63%) dengan titer antibodi rendah. Tingginya kadar titer antibodi setelah vaksin COVID-19 berhubungan dengan munculnya gejala atau reaksi sistemik KIPI. Kesimpulan: Terdapat hubungan kadar titer antibodi COVID-19 dengan KIPI pasca vaksinasi

Kata Kunci

Vaksin Astrazeneca; Titer antibodi; COVID-19; kejadian ikutan pasca-imunisasi (KIPI); sosiodemografi

Teks Lengkap:

PDF

Referensi

Djalante R, Lassa J, Setiamarga D, Sudjatma A, Indrawan M, Haryanto B, et al. Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020. Progress in Disaster Science. 2020;6.

Kementrian Kesehatan Republik Indonesia. Masyarakat Indonesia Sambut Baik Vaksinasi COVID-19. PromkesKemkesGoId. 2021;2021.

Alharbi NK, Al-Tawfiq JA, Alwehaibe A, Alenazi MW, Almasoud A, Algaisi A, et al. Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines. Infection and Drug Resistance. 2022;15(June):4127–36.

Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet. 2021;398(10296):213–22.

Kezia V, Ramatillah DL. Original Article INTENSIVE MONITROING OF SINOVAC VACCINE FOR SAFETY AND EFFICACY AMONG INDONESIAN POPULATION. 2022;14(2):44–8.

Raghotham S, Balamuralidhara V, Karuna K. Registration requirement and approval procedure of vaccines in Saudi Arabia. Research Journal of Pharmacy and Technology. 2019;12(9):4531–8.

Ahmed R, Lanier JG, Pamer E. Immuological Memory and Infection. Imunologi Of Infectin Diase. Washington D.C; 2002.

Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021;397(10269):72–4.

WHO. Introduksi Keamanan Vaksin, Klasifikasi KIPI. 2021;1–3.

Riester E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, et al. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. Journal of Virological Methods. 2021 Nov 1;297:114271.

Roche Diagnostics GmbH. Elecsys Anti-SARS-CoV-2 S Protocol. Roche Diagnostics International Ltd; 2021.

World Health Organization. Rekomendasi interim untuk penggunaan vaksin COVID-19 inaktivasi, CoronaVac, yang dikembangkan oleh Sinovac. Panduan Interim. 2021;1(4):1–7.

Kleebayoon A, Wiwanitkit V. Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations. Journal of the Formosan Medical Association. 2023;122(5):432–3.

Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine. 2020;383(18):1724–34.

Burton DR. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nature Reviews Immunology. 2023;23(November 2023):720–34.

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. 2021;27(7):1205–11.

Dai M, Tao L, Chen Z, Tian Z, Guo X, Allen-Gipson DS, et al. Influence of Cigarettes and Alcohol on the Severity and Death of COVID-19: A Multicenter Retrospective Study in Wuhan, China. Frontiers in Physiology. 2020;11(December):1–6.

Gaydos J, McNally A, Guo R, William Vandivier R, Simonian PL, Burnham EL. Alcohol abuse and smoking alter inflammatory mediator production by pulmonary and systemic immune cells. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2016;310(6):L507–18.

Haddad C, Bou Malhab S, Sacre H, Salameh P. Smoking and COVID-19: A Scoping Review. Tobacco Use Insights. 2021;14:1179173X2199461.

Usyal E, Gumus S, Bektore B, Bozkurt H, Gozalan A. Evaluation of Antibody Response After COVID-19 Vaccnation of Healthcare workers. Journal of Medical Virology. 2021;94(3).

Sari IP, Sriwidodo S. Perkembangan Teknologi Terkini dalam Mempercepat Produksi Vaksin COVID-19. Majalah Farmasetika. 2020;5(5):204.

Zulkarnain BS, Kundiman EMS, Aina L, Ardianto N, Meiliani F, Rachman MPA, et al. Evaluation of COVID-19 Vaccine Effectiveness Among Healthcare Workers Using Cascade Analysis. Jurnal Kesehatan. 2022;15(2):92–7.

Aisy SR, Rizal A, Simanjuntak BY. Vitamin C, Vitamin D dan Imunitas Pasien COVID-19. Journal of Nutrition College. 2023;12(1).

DOI: https://doi.org/10.24198/ijpst.v11i3.54268